Lloyd Paul Aiello, MD, PhD, Professor of Ophthalmology and Co-Director of the Diabetic Eye Disease Center of Excellence at Harvard Medical School, has been inducted into the Retina Hall of Fame for his contributions to the research and treatment of diabetic retinopathy. The Retina Hall of Fame was established in 2016 to honor the significant achievements and contributions of leaders in the field.... Read more about Lloyd Paul Aiello Inducted Into Retina Hall of Fame
Nearly 40 Harvard Ophthalmology faculty and trainees from our affiliates—including Beetham Eye Institute at Joslin Diabetes Center, Boston Children's Hospital, Mass. Eye and Ear, and VA Boston Healthcare System—participated in the American Academy of Ophthalmology Annual Meeting October 11-15 in San Francisco.... Read more about Highlights from the 2019 AAO Annual Meeting
New research findings may lead to development of new therapies to delay or prevent the development of diabetic eye disease.
Boston, Mass. — Researchers from the Schepens Eye Research Institute of Massachusetts Eye and Ear have shown that a slight increase in transforming growth factor beta (TGF-β), which is present in preclinical animal models with diabetic eye disease, protects retinal blood vessels from damage that commonly occurs in the early stages of the disease (known as diabetic retinopathy). Their findings, ...
Mass. Eye and Ear researchers describe, for the first time, an association between a defective myogenic response of blood vessels in the retina and early, accelerated development of retinopathy in patients with type 1 diabetes. The findings may lead to the development of targeted therapies to delay or prevent the development of diabetic retinopathy in this population.